Special Issue

Antibiotic Resistance and Antimicrobial Use in Elderly Patients, 2nd Edition

Message from the Guest Editors

The first edition of the Special Issue "Antibiotic Resistance and Antimicrobial Use in Elderly Patients" was published in 2021. It is a successful collection comprising eight excellent papers, and it has encouraged us to publish a second edition within the same area. As a continuation of the first Special Issue, this second edition focuses on antimicrobial use in elderly and very elderly patients, including (but not limited to) the following topics:

- Specific approaches to antimicrobial therapy in elderly populations;
- Antimicrobial use in the multi-therapy and multimorbid patients;
- Recurrent infections, sepsis, and antimicrobial therapy in frail patients;
- Antibiotic stewardship in elderly people;
- Changes in microbiota and antibiotic therapy in the elderly;
- Role of new technologies (bacteriophages/probiotics, machine learning, etc.) to control antimicrobialresistant organisms in the elderly.

Guest Editors

Dr. Marcello Covino

Emergency Medicine, Fondazione Policlinico, Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

Dr. Giuseppe De Matteis

Internal Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Deadline for manuscript submissions

31 January 2025



an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/212418

Antibiotics
MDPI, Grosspeteranlage 5

4052 Basel, Switzerland Tel: +41 61 683 77 34 antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 7.3 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

